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Retinoids are micronutrients that are stored as retinyl esters in the retina and hepatic stellate cells (HSCs). HSCs
are key players in fibrogenesis in chronic liver diseases. The enzyme responsible for hydrolysis and release of
retinylesters from HSCsisunknownandtherelationshipbetweenretinoid metabolismand liverdiseaseremains
unclear. We hypothesize that the patatin-like phospholipase domain-containing 3 (PNPLA3) protein is involved
in retinol metabolism in HSCs. We tested our hypothesis both in primary human HSCs and in a human cohort of
subjects with non-alcoholic fatty liver disease (N 5 146). Here we show that PNPLA3 is highly expressed in
human HSCs. Its expression is regulated by retinol availability and insulin, and increased PNPLA3 expression
results in reduced lipid droplet content. PNPLA3 promotes extracellular release of retinol from HSCs in response
to insulin. We also show that purified wild-type PNPLA3 hydrolyzes retinyl palmitate into retinol and palmitic
acid. Conversely, this enzymatic activity is markedly reduced with purified PNPLA3 148M, a common mutation
robustly associated with liver fibrosis and hepatocellular carcinoma development. We also find the PNPLA3
I148M genotype to be an independent (P 5 0.009 in a multivariate analysis) determinant of circulating retinol-
binding protein 4, a reliable proxy for retinol levels in humans. This study identifies PNPLA3 as a lipase respon-
sible for retinyl-palmitate hydrolysis in HSCs in humans. Importantly, this indicates a potential novel link
between HSCs, retinoid metabolism and PNPLA3 in determining the susceptibility to chronic liver disease.
INTRODUCTION
Retinoids are liposoluble micronutrients that are highly enriched
in the retina and stellate cells (1,2). Besides playing a major
physiological role in vision, they are also involved in the
regulation of cell proliferation and differentiation (3,4). In add-
ition, retinoids are used in the treatment of malignancies (4,5)
and have been shown to prevent hepatocellular carcinoma
(6,7). In humans, retinoids are absorbed in the intestine and trans-
ported in the form of retinyl esters by chylomicrons to the liver
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(8). Retinyl esters are hydrolyzed to retinol in hepatocytes and
then transferred to hepatic stellate cells (HSCs) and stored as
retinyl palmitate in lipid droplets (9). When needed, the retinol
stored in lipid droplets can be released to reach the specific
sites where it exerts its physiological functions (10). In the
blood stream, retinol is transported by the retinol-binding
protein 4 (RBP4) (11), a protein belonging to the lipocalin
family synthesized by hepatocytes (12). The plasma levels of
RBP4 strongly correlate with plasma retinol levels (13). Further-
more, the RBP4 genetic locus is the major genetic determinant of
plasma retinol levels (14).
In response to liver damage, HSCs are activated from a quies-
cent to a profibrotic state (15); importantly, this process is
coupled to release of retinol (10). However, the lipases respon-
sible for the release of retinol from HSCs in response to metabol-
ic stimuli are not known, and the metabolic relevance of this
event is still not understood (1,2).
Patatin-like phospholipase domain-containing 3 (PNPLA3)
has a lipase activity against triglycerides in human and murine
hepatoma cell lines (16,17). A naturally occurring sequence vari-
ation (rs738409) resulting in a isoleucine (I) to methionine (M)
substitution at position 148 (I148M) (18) of the protein is the
most robustly replicated genetic variant associated with liver
damage (19), hepatic neutral fat retention (17) and progression
to chronic liver disease (20–23). Despite the strong associations,
the underlying mechanism remains unknown.
Here, we hypothesized that PNPLA3 is involved in retinol me-
tabolism in HSCs. We examined the regulation of PNPLA3 in re-
sponse to changes in retinol availability and metabolic needs,
exemplified by insulin, in primary human HSCs (pHSCs). Fur-
thermore, we investigated the effect of the I148M mutation on
retinol metabolism in human HSCs and we tested for differences
in circulating levels of RBP4 among individuals carrying differ-
ent PNPLA3 I148M genotypes.
RESULTS
PNPLA3 is highly expressed in human HSCs
We performed an extensive analysis ofPNPLA3mRNA expres-
sion in human tissues (Supplementary Material) and found the
highest expression in the retina and liver (Fig. 1A and Supple-
mentary Material, Fig. S1). We next evaluated the relative ex-
pression levels of PNPLA3 within the liver in primary human
hepatocytes and HSCs. PNPLA3 mRNA and protein expression
levels were high in pHSCs compared with hepatocytes; the
levels of PNPLA3 were also high in comparison with
PNPLA2, the major triglyceride esterase in hepatocytes and adi-
pocytes (Fig. 1B and C). Finally, we examined the protein levels
of three lipases (24) that have been proposed as candidate for the
retinyl-esterase activity. The protein levels of all three candidate
lipases were almost undetectable in LX-2, an immortalized
human HSC line (Supplementary Material, Fig. S2).
PNPLA3 is regulated by retinol availability in human HSCs
To characterize the regulation of PNPLA3 expression in HSCs in
response to retinol availability, we incubated pHSCs with or
without retinol and palmitic acid for up to 48 h. In the presence
of retinol and palmitic acid, we observed a time-dependent
increase in lipid droplet accumulation paralleled by a downregu-
lation of PNPLA3 (Fig. 2A–C). Depletion of retinol and
palmitic acid resulted in a time-dependent reduction in lipid
droplet accumulation and an increase of PNPLA3 expression
(Fig. 2D–F). Identical results were obtained in LX-2 cells
(data not shown).
Insulin-mediated upregulation of PNPLA3 promotes
a reduction of lipid droplet content in human HSCs
PNPLA3 is upregulated by insulin through sterol regulatory
element-binding protein 1C in hepatocytes (25), and here we
observed higher protein levels of PNPLA3 in pHSCs after incu-
bation with insulin (Supplementary Material, Fig. S3). We also
Figure 1. PNPLA3 is highly expressed in human retina, hepatocytes and HSCs.
(A) PNPLA3 mRNA expression in human tissues assessed by qPCR. The tissue
with the highest CT value was assigned the value of 1. (B) PNPLA3 mRNA ex-
pression in pHSCs, primary human hepatocytes (positive control) and human
colon carcinoma (CACO-2) cells (negative control). Lecithin retinol acyl trans-
ferase (LRAT) and albumin were used as references for pHSCs and hepatocytes,
respectively. (C) Immunoblot showing PNPLA3 and PNPLA2 protein expres-
sion in pHSCs, primary human hepatocytes (Hep) and CACO-2 cells. Calnexin
was used as a loading control.
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observed a striking reduction in lipid droplet content associated
with PNPLA3 upregulation after insulin incubation (Fig. 3A–C).
This effect was abolished after PNPLA3 knockdown by siRNA
(Fig. 3A–C), thus suggesting a direct role of PNPLA3 in insulin-
dependent regulation of lipid droplet content in pHSCs. Identical
results were obtained in LX-2 cells (Supplementary Material,
Fig. S4).
PNPLA3 promotes extracellular release of retinol
from human HSCs but not triglyceride hydrolysis
To establish the specific role of PNPLA3 in retinyl-palmitate
hydrolysis, we investigated the effect of PNPLA3 silencing on
the intracellular content of retinyl palmitate and the extracellular
release of retinol from differentiated LX-2 cells upon retinol
depletion from the culture medium. In the presence of control
siRNA, the intracellular content of retinyl palmitate decreased
over time in parallel with an increased release of retinol
(Fig. 4A and B). By contrast, treatment with PNPLA3 siRNA
reduced both the intracellular depletion of retinyl palmitate
and the extracellular release of retinol (Fig. 4A and B). These
data suggest that PNPLA3 is involved in the hydrolysis of
retinyl palmitate to retinol and palmitic acid in HSCs.
To test PNPLA3 lipase activity on glycerolipids in stellate
cells, we examined the impact of PNPLA3 I148M mutation on
triglyceride storage in LX. Cells overexpressing the 148I wild
type or 148M mutant PNPLA3 were incubated with radiolabeled
Figure 2. Intracellular lipid accumulation modulates PNPLA3 expression in pHSCs. (A) Lipid droplet content visualized by ORO-staining in pHSCs incubated with
retinol and palmitic acid for the indicated times. (B) ORO-stained area quantified by Biopix. (C) Immunoblot showing PNPLA3 expression in pHSCs under conditions
described in (A). (D) Lipid droplet content visualized by ORO staining in pHSCs incubated with retinol and palmitic acid for 48 h and then in medium without retinol-
palmitic acid for the indicated times. (E) ORO-stained area quantified by BioPix. (F) Immunoblot showing PNPLA3 expression in pHSCs under conditions described
in (D). Scale bars: 10 mm.
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palmitic acid and intracellular triglycerides were examined
after lipid fractionation. No differences in the intracellular trigly-
ceride storage were observed between cells overexpressing the
PNPLA3 wild type or the mutant form or transfected with the
empty vector (Supplementary Material, Fig. S5), suggesting
the absence of PNPLA3 triglyceride hydrolase activity in stellate
cells.
Human PNPLA3 I148M is a loss-of-function mutation
in HSCs
To further test the lipase activity and the effect of the I148M mu-
tation, we overexpressed PNPLA3 148I wild type and the 148M
mutant form in HSCs pretreated with retinol (Supplementary
Material). Acute overexpression of PNPLA3 148I led to a strik-
ing reduction in lipid droplet content, whereas acute overexpres-
sion of PNPLA3 148M had no effect (Fig. 5A–C). Similar
results were obtained in LX-2 cells (Supplementary Material,
Fig. S6). These data indicate that the PNPLA3 148M is a
loss-of-function mutation in terms of regulation of lipid
droplet metabolism in human HSCs.
To assess the role of PNPLA3 in HSCs on the intracellular tri-
glyceride content of hepatocytes, we performed a co-culture ex-
periment. LX-2 and HEPG2 cells were co-cultured in a transwell
plate. LX-2 cells were transiently transfected with PNPLA3
148I, 148M or the empty vector and the intracellular triglyceride
content of hepatocytes was assessed by lipid fractionation after
incubation with palmitic acid and radiolabeled glycerol. We
observed no differences in intracellular hepatocyte triglycerides
after co-culture with LX-cells overexpressing PNPLA3148I or
Figure 3. Insulin-mediated PNPLA3 upregulation reduces lipid droplet content in pHSCs. (A) Lipid droplet content visualized by ORO staining in pHSCs incubated
w/o retinol-palmitic acid for 48 h, transfected with PNPLA3 or control siRNA and incubated w/o insulin for further 48 h. Scale bars: 10 mm. (B) ORO-stained area
quantified by BioPix. ∗P , 0.05. (C) Immunoblot showing PNPLA3 and PNPLA2 expression in pHSCs under conditions described in (A).
Figure 4. PNPLA3 silencing reduces retinol release in LX-2 cells. (A) Intracel-
lular [3H]-retinyl palmitate and (B) extracellular [3H] retinol from LX-2 cells
transfected with PNPLA3 or control siRNA, incubated with [3H]-retinol-
palmitic acid and chased in cold medium for the indicated times. ∗P , 0.05.
4080 Human Molecular Genetics, 2014, Vol. 23, No. 15
148M (Supplementary Material, Fig. S7). These data suggest
that the triglyceride retention in hepatocyte is independent of
retinol release by stellate cells.
PNPLA3 148I but not 148M has retinyl esterase activity
in vitro
To verify whether retinyl palmitate is a direct enzymatic sub-
strate of PNPLA3, we purified the PNPLA3 148I wild type and
the 148M mutant after recombinant production in a well-
established eukaryotic host system (Pichia pastoris) (26,27).
We incubated the purified proteins with radiolabeled retinyl
[14C] palmitate and observed a concentration-dependent
release of palmitic acid with PNPLA3 148I but not with the
148M protein (Fig. 5D). When we calculated the Km and Vmax
by incubating the purified proteins with increasing concentra-
tions of substrate, we observed a Vmax reduction from 5.4 to
2.1 nmol/mg/min and a Km increase from 4.9 to 29.7 mM in the
148M mutant protein compared with the 148I wild type
(Fig. 5E). Thus, we confirmed that PNPLA3 148I has retinyl-
palmitate lipase activity and that the I148M substitution results
in loss of function.
PNPLA3 has no retinyl-esterase activity in hepatocytes
To test if PNPLA3 in hepatocytes has a retinyl-esterase activity,
we incubated cell lysates of rat hepatocytes (McA-RH7777
cells) stably overexpressing the human PNPLA3 wild type or
148M mutant protein (17) with radiolabeled retinyl palmitate
and measured the palmitic acid release. A retinyl-esterase activ-
ity was observed for both lysates with no differences between the
wild-type and the mutant protein (Supplementary Material,
Fig. S8).
PNPLA3 148M homozygotes have lower circulating levels
of RBP4
To test the hypothesis that PNPLA3 protein is involved in retinol
metabolism in humans, we compared RBP4 levels between car-
riers of the 148I allele and 148M homozygotes in a cohort of 146
individuals with biopsy proven non-alcoholic fatty liver disease
(see Table 1; Supplementary Material, Table S1 for character-
istics). A 12% reduction in RBP4 was found in PNPLA3 148M
Figure 5. Overexpression of wild type but not mutant PNPLA3 reduces lipid
droplet content in pHSCs and the mutation induces retinyl-hydrolase activity
loss of function. (A) Lipid droplets visualized by ORO-staining in pHSCs over-
expressing V5-tagged 148I or 148M PNPLA3 and incubated with retinol-
palmitic acid for 48 h. Empty vector (EV) was used as negative control. (B)
ORO-stained area quantified by BioPix. (C) Immunoblot showing transfection
efficiency. (D) [14C]-palmitate production after incubation of the indicated
amounts of purified human 148I and 148M PNPLA3 with retinyl [14C] palmitate
for 15 min. (E) PNPLA3 148I and 148M purified proteins were incubated with
increasing concentrations of radiolabeled retinyl palmitate. Released palmitic
acid was measured by scintillation counting. Values were fitted to Michaelis–
Menten kinetics curves to determine Vmax and Km values.
Table 1. RBP4 analysis cohort description
Cohort characteristic
N 146
Men (%) 78
Age (years) 49+12
BMI (kg/m2) 27+3
Glucose (mg/dl) 98+27
RBP4 (mg/ml) 51+14
NASH (%) 45
Diabetes or IFG (%) 35
PNPLA3 I148M genotype
II (%) 40
IM (%) 44
MM (%) 16
N, number; BMI, body mass index; RBP4, retinol-binding protein 4; NASH,
non-alcoholic steatohepatitis; IFG, impaired fasting glucose; PNPLA3,
patatin-like phospholipase domain-containing protein 3; II, homozygous for the
PNPLA3 148I allele; IM, heterozygous; MM, homozygous for the PNPLA3
148M allele.
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homozygotes compared with 148I allele carriers (II + IM ¼
52+ 13 mg/mL, MM ¼ 46+ 17 mg/mL, P ¼ 0.010). In a
multivariate analysis, homozygosity for the M allele remained
an independent predictor of lower RBP4 levels (P ¼ 0.009,
Table 2) after adjustment for factors previously associated
with RBP4 plasma levels (age, gender, non-alcoholic steatohe-
patitis, body mass index and type 2 diabetes/impaired fasting
glucose). These data are consistent with the hypothesis that
PNPLA3 is involved in retinol release from HSCs and that intra-
cellular retention of retinol occurs in 148M homozygotes.
DISCUSSION
Here we showed that PNPLA3 was highly expressed in retina
and liver, with higher expression compared to other candidate
retinyl-ester lipases in stellate cells and higher expression in
pHSCs than in hepatocytes. PNPLA3 expression in pHSCs
was regulated by retinol availability and insulin and was inverse-
ly related to lipid droplet content. Importantly, we showed that
human PNPLA3 had a retinyl-esterase activity ex vivo and
in vitro and that the I148M mutation resulted in a loss of this
enzymatic activity.
A previous study reported high expression of PNPLA3 in the
liver and skin (25). We showed that PNPLA3 was highly
expressed in the retina and liver but we also observed an appre-
ciable amount of PNPLA3 mRNA in the skin, consistently with
the previous study. It is not possible to compare the retina mRNA
PNPLA3 levels between the two studies.
We observed that endogenous PNPLA3 in pHSCs was down-
regulated by retinol incubation and upregulated by retinol deple-
tion. These observations are consistent with the concept that
PNPLA3 expression is (1) repressed when retinol is plentiful,
resulting in storage of retinyl palmitate in lipid droplets and (2)
induced in response to retinol deficiency, resulting in hydrolysis
of retinyl palmitate and extracellular release of retinol.
Insulin has been shown to induce PNPLA3 expression in
hepatocytes (25) and to activate HSCs (28). We observed that
insulin treatment-induced PNPLA3 upregulation in pHSCs.
Moreover, the insulin-induced increase in PNPLA3 levels was
associated with a reduction of intracellular lipid droplets. Both
these responses were abolished after PNPLA3 silencing. To-
gether with our observation that PNPLA3 overexpression pro-
moted a reduction of lipid droplets, these data indicate that
PNPLA3 plays a specific role in intracellular lipid droplet re-
modeling in response to insulin in HSCs. It is noteworthy that
changes in intracellular retinyl-ester content have been asso-
ciated with HSC modifications during chronic liver damage (10).
We observed a time-dependent decrease in intracellular
retinyl ester and a parallel extracellular release of retinol when
pHSCs were preincubated with retinol and palmitate and then
chased in retinol-free medium. These responses were reduced
after PNPLA3 knockdown, suggesting that PNPLA3 has
retinyl-esterase activity. The residual intracellular esterase ac-
tivity observed after PNPLA3 knockdown may be explained
by the presence of other lipases in HSCs.
Given the robust genetic evidence showing an association of
PNPLA3 148M with liver neutral fat content and chronic liver
diseases (29), we next examined the effect of acute overexpres-
sion of PNPLA3 148M in pHSCs. In contrast to the dramatic re-
sponse observed in cells transfected with wild-type PNPLA3
148I, there was no difference in lipid droplet content between
HSCs transfected with PNPLA3 148M or with an empty
vector as a control. These data are in line with our previous
study in hepatocytes, showing that overexpression of human
PNPLA3 148I but not 148M promotes intracellular triglyceride
lipase activity (17).
We have shown a lipase activity of the purified wild-type
protein on retinyl palmitate. In a previous study that examined
the PNPLA3 enzymatic activity on various glycerolipids, we
found a predominant lipase activity on triglycerides and digly-
cerides but not on monoglycerides, indicating relative substrate
specificity (30). Furthermore, PNPLA3 wild type has an
12-fold higher enzymatic affinity (Km 4.9 versus 61.1) and a
3-fold lower enzymatic activity (Vmax 14.7 versus 5.4) for the
retinyl palmitate as compared with triglycerides (30). The
PNPLA3 mutant form has a comparable reduction in both activ-
ity and affinity for triglycerides and retinyl palmitate (30).
We also tested if PNPLA3 wild-type and mutant protein has a
retinyl-esterase activity in hepatocytes. We observed an overall
retinyl-esterase activity but no differences in cells stably overex-
pressing the human PNPLA3 148I wild-type and 148M mutant
protein. This suggests that the overall hepatocyte retinyl-
esterase activity depends on the previously identified esterases
(2), and PNPLA3 may not be active as a retinyl esterase in the
hepatocyte. Furthermore, we failed to observe differences in
hepatocyte intracellular fat content after co-culture with LX-2
cells overexpressing PNPLA3 148I or 148M, suggesting that
the triglyceride retention in hepatocyte is independent of
retinol release.
In humans, retinol in circulation is predominantly bound to the
RBP4 (11), and RBP4 levels are highly correlated (R2 ¼ 0.8) with
circulating retinol (13). We examined the RBP4 levels in a cohort
of 146 individuals stratified by PNPLA3 genotypes.To test if indi-
viduals with the 148M mutations had lower RBP4 protein we
chose to use a recessive model. This decision was based on our
earlier study showing that PNPLA3 I148M is associated with
hepatocellular carcinoma under a recessive model (31). Homozy-
gotes for the 148M allele had lower RBP4 compared with carriers
of the 148I allele. Given that circulating retinol levels under
fasting conditions are a function of retinol mobilization from
HSCs these data are consistent with a model in which the
PNPLA3 148M protein induces an intracellular retention of
retinol due to a loss of the retinyl-palmitate esterase activity.
Table 2. Multivariate analysis of factors modulating circulating RBP4 levels
b P-value
NASH 0.067 0.529
BMI 0.202 0.063
Age 0.004 0.966
Gender 0.206 0.042
DM or IGF 20.048 0.633
PNPLA3 genotype 20.250 0.009
Data were analyzed using linear regression analysis under a recessive model and
after adjusting for confounding factors. Values were log transformed before
entering the model if not normally distributed.
RBP4, retinol-binding protein 4; NASH, non-alcoholic steatohepatitis; BMI,
body mass index; DM, diabetes mellitus; IFG, impaired fasting glucose;
PNPLA3, patatin-like phospholipase domain-containing protein 3.
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HSCs are involved in fibrogenesis (32) and retinoids have an
important role in regulating cell growth, differentiation, carcino-
genesis (4) and in the regulation of lipid metabolism in the liver
(33). The present study identifies PNPLA3 as a possible link
between HSCs, retinoids and chronic liver disease.
In mouse liver,Pnpla3mRNA has been shown to be expressed
in HSCs at lower levels than in hepatocytes (25). However,
tissue-specific differences between mouse and human in
PNPLA3 have already been shown (25,34).
We propose that PNPLA3 represents a retinol gatekeeper in
HSCs promoting release of retinol in response to metabolic
needs. Additional studies are warranted to test whether
PNPLA3 is involved in the transdifferentiation of HSCs in re-
sponse to liver damage and to understand the role played by
the I148M PNPLA3 variant in HSCs in the susceptibility
toward hepatic fibrogenesis and carcinogenesis.
In summary, we identify PNPLA3 as the first retinyl-palmitate
lipase in HSCs and we also show that the 148M mutation leads to
a loss of this function. The importance of our study resides in
establishing a new role for PNPLA3 in retinoid metabolism in
HSCs with possible important implications for liver fibrosis
and hepatocellular carcinoma susceptibility.
MATERIALS AND METHODS
Cell culture
Primary human HSCs (pHSCs; ScienCell) were grown in SteCM
medium (ScienCell) in T-75 flasks coated with poly-L-lysine.
When confluent, cells were trypsinized (0.05% trypsin/
0.53 mM EDTA) and seeded at a ratio of 1 : 3. Subsequent
passages were performed every 6 days. Immortalized human
HSCs (LX-2) were kindly provided by Professor Scott
L. Friedman (Mount Sinai School of Medicine). LX-2 cells
were grown in high glucose DMEM containing 10% fetal
bovine serum in T-75 flasks. When confluent, LX-2 cells were
passaged as for pHSCs. Primary fresh human hepatocytes were
purchased from 3H Biomedical. Human hepatoma (HEPG2)
cells (ATCC) were grown in high glucose DMEM containing
10% fetal bovine serum in T-75 flasks according to the manufac-
turer’s instructions. Colon carcinoma (CACO-2) cells (ATCC)
were grown in MEM with Earl’s salts according to the manufac-
turer’s instructions. Cells were seeded in 24-well plates with
cover slips (for Oil Red O staining, see Supplementary Material)
or in 6-well plates (for immunoblot and mRNA expression
analyses, see Supplementary Material).
Analysis of retinyl-palmitate metabolism
Growing medium was supplemented with 10 mM retinol, 300 mM
palmitic acid and 0.6 mCi/ml of [11,12-3H]-retinol and vigor-
ously mixed to aid esterification to retinyl palmitate. Cells
were seeded in 6-well plates and transfected with PNPLA3
siRNA or control siRNA for 12 h (Supplementary Material).
Cells were then incubated with radiolabelled medium for 36 h,
and retinol release was chased in cold medium for 0, 2, 4, 8
and 24 h. Cells and media were harvested at each time point
and lipids extracted in 10 ml of Folch solution [chloroform :
methanol (2 : 1 v/v) plus 2 ml of acidified solution (0.2 M
orthophosphoric acid)]. After vigorous mixing and centrifuga-
tion at 3000g for 15 min at 48C, the upper water phase was dis-
charged and the lower organic phase was dried under nitrogen
stream. Lipids were resuspended in chloroform and separated
on a Silica plate by two-phase thin-layer chromatography (first
mobile phase: chloroform : methanol : H2O 65 : 25 : 4; second
mobile phase petroleum ether : diethyl ether : acetic acid 60 :
40 : 1). Lipids were next stained with iodine vapor and bands
corresponding to retinol (for media samples) and retinyl
palmitate (for cell samples) were counted for tritium by scintil-
lation counting.
Retinyl-palmitate hydrolase activity assay
PNPLA3 protein was purified as previously described (30).
Briefly, 148I and 148M PNPLA3 cDNA were cloned in a
pPICZ-B vector and transformed into P. pastoris for large-scale
protein production. Proteins were solubilized and purified from
the membrane fraction by Ni-affinity chromatography and sub-
sequently used for the retinyl-palmitate hydrolase activity assay.
Increasing amounts of purified 148I wild type and 148M
mutant PNPLA3 protein were incubated with retinyl [14C]
palmitate for 30 min at 378C. The reaction was terminated
by adding heptane : chloroform : methanol (1 : 1.25 : 1.41),
mixed, and centrifuged at 3000g for 15 min. A 1-ml aliquot of
upper (water) phase was taken and released [14C]-palmitic acid
was measured by scintillation counting. GraphPad Prism 5 soft-
ware was used for Michaelis–Menten curve fitting andVmax and
Km value calculation.
Study cohort
PNPLA3 I148M genetic variant was genotyped in 146 indivi-
duals with biopsy proven non-alcoholic fatty liver disease diag-
nosed between January 2008 and January 2013 at Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Uni-
versita` degli Studi di Milano, Milan, Italy. Other causes of liver
disease were ruled out, including increased alcohol intake (.30/
20 g/day for M/F), viral and autoimmune hepatitis, hereditary
hemochromatosis and alpha1-antitrypsin deficiency. This
cohort recruitment has been previously been described (35),
and this analysis includes a total of 146 individuals. Genotyping
was performed as previously described (21). The study protocol
was conformed to the ethical guidelines of the 1975 Declaration
of Helsinki and was performed according to the recommenda-
tions of the Ethics Committee of the Fondazione IRCCS Ca’
Granda. Written informed consent was obtained from each
patient. Cohort characteristics are shown in Table 1 and Supple-
mentary Material, Table S1. Serum samples were collected at the
time of liver biopsy in all patients after overnight fasting;
aliquots were stores and were maintained at 2808C until the
analytical procedure. Plasma RBP4 levels were assessed by
enzyme-linked immunosorbent assay (Abcam) according to
manufacturer’s instruction. Non-alcoholic steatohepatitis has
been defined as presence of steatosis, ballooning and lobular in-
flammation (36). Type 2 diabetes and impaired fasting glucose
have been defined according to the American Diabetes Associ-
ation criteria (37).
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Statistics
Data from in vitro and ex vivo experiments were analyzed using
two-tailed Student’s t-test. P-values of ,0.05 were considered
significant and indicated as ∗ in figures. Bar graphs in figures
show mean+SD of three experiments unless differently speci-
fied. Differences in RBP4 levels across PNPLA3 I148M geno-
types in humans were analyzed using linear regression analysis
or general linear model under a recessive model and after adjust-
ing for confounding factors. Post hoc analyses to compare the
differences in RBP4 levels between paired genotypes was
carried out by Fisher’s least significant difference test. Values
have been log transformed before entering the model if not nor-
mally distributed. Statistical analyses were carried out in IBM
SPSS 19.0 for Windows (SPSS, Chicago, IL, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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